Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Non-Squamous Non-Small Cell Lung Cancer
Adult Solid Tumor

Interventions

BIOLOGICAL: Visugromab
DRUG: Matching placebo for visugromab
BIOLOGICAL: Pembrolizumab 200 mg Q3W
DRUG: Pemetrexed 500 mg/m^2
DRUG: Carboplatin AUC 5

Sponsor

CatalYm GmbH